Media coverage about Repligen Corporation (NASDAQ:RGEN) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repligen Corporation earned a news impact score of 0.20 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.4458114346905 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern’s analysis:

Several equities analysts recently commented on the stock. Stephens reaffirmed an “overweight” rating and set a $50.00 target price on shares of Repligen Corporation in a report on Tuesday, September 26th. Jefferies Group LLC reaffirmed a “hold” rating and set a $40.00 target price on shares of Repligen Corporation in a report on Thursday, September 14th. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. William Blair assumed coverage on shares of Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating on the stock. Finally, TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $45.40.

Shares of Repligen Corporation (NASDAQ:RGEN) traded up $1.38 during trading on Friday, reaching $38.92. 200,208 shares of the company’s stock were exchanged, compared to its average volume of 443,372. The firm has a market cap of $1.31 billion, a P/E ratio of 75.47, a price-to-earnings-growth ratio of 2.60 and a beta of 1.05. The company has a current ratio of 11.87, a quick ratio of 10.29 and a debt-to-equity ratio of 0.51.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. During the same period in the prior year, the company posted $0.16 EPS. The company’s revenue was up 11.0% compared to the same quarter last year. analysts anticipate that Repligen Corporation will post 0.59 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.